While KRAS mutations in cutaneous melanoma occur less frequently than BRAF or NRAS mutations, KRAS-linked signaling has garnered attention in other malignancies and exhibits the potential to influence melanoma cell proliferation and phenotypic plasticity (14). This evidence concerns the gene KRAS and cutaneous melanoma.